Added to YB: 2026-01-07
Pitch date: 2026-01-05
HRMY [bullish]
Harmony Biosciences Holdings, Inc.
+2.48%
current return
Author Info
Contrarian Cashflows publishes a monthly deep dive on a new value stock. Sign up for the newsletter.
Company Info
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States.
Market Cap
$2.2B
Pitch Price
$36.64
Price Target
N/A
Dividend
N/A
EV/EBITDA
6.56
P/E
11.80
EV/Sales
2.00
Sector
Pharmaceuticals
Category
value
Monday Delight: 05/01/2026 - Harmony Biosciences Holdings, Inc.
HRMY (quick overview): Commercial-stage rare neurological disorders biotech w/ WAKIX generating high-margin revenue. 22.5% ROIC, 12.8x P/E, $2.3B mkt cap. Profitable w/ consistent share buybacks, rare in biotech. Pipeline expansion via R&D + M&A. Strong margins + disciplined capital allocation.
Read full article (1 min)